Greenfield Savings Bank Reduces Stake in Amgen Inc. $AMGN

Greenfield Savings Bank lowered its position in Amgen Inc. (NASDAQ:AMGN) by 1.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,234 shares of the medical research company’s stock after selling 49 shares during the period. Greenfield Savings Bank’s holdings in Amgen were worth $903,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of AMGN. Wealth Preservation Advisors LLC purchased a new stake in shares of Amgen during the 1st quarter valued at about $25,000. Pinney & Scofield Inc. bought a new stake in Amgen during the fourth quarter valued at approximately $26,000. First Pacific Financial grew its position in shares of Amgen by 304.5% during the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 67 shares during the period. CBIZ Investment Advisory Services LLC increased its position in Amgen by 1,214.3% in the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock worth $29,000 after buying an additional 85 shares in the last quarter. Finally, Activest Wealth Management raised its stake in Amgen by 3,433.3% during the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock worth $33,000 after acquiring an additional 103 shares during the period. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on AMGN shares. Guggenheim began coverage on Amgen in a research report on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 price objective on the stock. William Blair reissued an “outperform” rating on shares of Amgen in a report on Tuesday, June 24th. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Piper Sandler boosted their target price on shares of Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a report on Monday, August 25th. Finally, Bank of America upped their target price on shares of Amgen from $252.00 to $261.00 and gave the stock an “underperform” rating in a research report on Wednesday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and an average target price of $304.43.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.76% of the company’s stock.

Amgen Price Performance

Amgen stock opened at $276.39 on Friday. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $339.17. The company has a market cap of $148.80 billion, a price-to-earnings ratio of 22.60, a PEG ratio of 2.46 and a beta of 0.49. The firm’s fifty day moving average is $292.54 and its 200 day moving average is $291.66. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same period in the previous year, the firm posted $4.97 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.4%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s dividend payout ratio (DPR) is presently 77.84%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.